In vivo microdialysis studies of striatal level of neurotransmitters after haloperidol and chlorpromazine administration

Indian Journal of Experimental Biology

Volumn 47, Issue 2, 2009, Pages 91-97

  Kulkarni, Shrinivas K ^a,b   Bishnoi, Mahendra ^a   Chopra, Kanwaljit ^b  

^a PANJAB UNIVERSITY   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

Atypical antipsychotics; In vivo microdialysis; Neurotransmitters; Tardive dyskinesia

Indexed keywords

RATTUS;

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CHLORPROMAZINE; DOPAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; NORADRENALIN; SEROTONIN;

ANIMAL; ANIMAL BEHAVIOR; ARTICLE; BASAL GANGLION; CATALEPSY; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFECT; DYSKINESIA; MALE; MICRODIALYSIS; PATHOPHYSIOLOGY; RAT; WISTAR RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; BEHAVIOR, ANIMAL; CATALEPSY; CHLORPROMAZINE; CORPUS STRIATUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; HALOPERIDOL; MALE; MICRODIALYSIS; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; RATS; RATS, WISTAR; SEROTONIN;

EID: 69249209987     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Hauber W, Involvement of basal ganglia transmitter systems in movement initiation, Prog Neurobiol, 56 (1998) 507.
2. Brotchie J M, Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease, Mov Disord, 13 (1998) 871.
3. Cara D B, Dusticier N, Forni C, Lievens J C & Daszuta A, Serotonin depletion produces long lasting increase in striatal glutamatergic transmission, J Neurochem, 78 (2001) 240.
4. Costall B, Fortune D H, Naylor R J, Mardsen C D & Pycock C, Serotonergic involvement with neuroleptic catalepsy, Neuropharmacology, 14 (1975) 859.
5. Kulkarni S K, Arzi A & Kaul P N, Modification of drug-induced catatonia and tremors by quapazine in rats and mice, Jpn J Pharmacol, 30 (1980)129.
6. Neal-Beliveau B S, Joyce J N & Lucki I, Serotonergic involvement in haloperidol-induced catalepsy, J Pharmacol Exp Ther, 265 (1993) 207.
7. Casey D E, Tardive Dyskinesia: pathophysiology and animal models, I Jour Psychiatry, 61 (2000) 5.
8. Naidu P S & Kulkarni S K, Excitatory mechanisms in neuroleptic induced vacuous chewing movements: possible involvement of calcium and nitric oxide, Behav Pharmcol, 12 (2001) 209.
9. Tsai G C, Golf D C, Chang R W, Flood J, Baer L & Coyle J T, Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia, Am J Psych, 155 (1998) 1207.
10. Bishnoi M, Kumar A, Chopra K & Kulkarni S K. Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia, Indian J Exp Biol, 45 (2007) 175.
11. Lau Y S, Petroske E, Meredith G E & Wang J Q, Elevated neuronal nitric oxide synthase expression in chronic haloperidol treated rats, Neuropharmacology, 45 (2003) 986.
12. Ninan I & Kulkarni S K, Quinpirole, 8-OH-DPAT and ketanserin modulate catalepsy induced by high doses of atypical antipsychotics, Methods Find Exp Clin Pharmacol. 21 (1999) 603.
13. Naidu P S, Singh A & Kulkarni S K, Quercetin, a bioflavonoid attenuated haloperidol induced orofacial dyskinesia, Neuropharmacology, 44 (2003) 1100.
14. Bishnoi M, Chopra K & Kulkarni S K, Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain, Pharmacol Biochem Behav, 88 (2008) 511.
15. Nowak P, Dabrowska J, Bortel A, Izabela B, Kostrzewa R M & Brus R, Prenatal cadmium and ethanol increase amphetamine-evoked dopamine release in rat striatum, Neurotoxicol Teratol, 28 (2006) 563.
16. Bongiovanni R, Young D, Newbould E & Jaskiw G E, Increased striatal dopamine synthesis is associated with decreased tissue levels of tyrosine, Brain Res, 1115 (2006) 26.
17. Church W H, Column Chromatography analysis of Brain tissue: An advanced laboratory exercises for neuroscience majors, Undergraduate Neurosci Edu Spring, 3(2) (2005) A36.
18. Bishnoi M, Chopra K & Kulkarni S K. Neurochemical changes associated with chronic administration of typical antipsychotics and its relationship with tardive dyskinesia, Methods Find Exp Clin Pharmacol, 29 (2007) 211.
19. Silva S R, Futuro-Neto H A & Pires J G, Effects of 5-HT3 receptor antagonists on neuroleptic-induced catalepsy in mice, Neuropharmacology, 34 (1995) 97.
20. Pires J G, Costa P G, Saraiva F P, Bonikovski V & Futuro Neto H A, Gender-related differences in the effects of nitric oxide donors on neuroleptic-induced catalepsy in mice, Braz J Med Biol Res, 36 (2003) 239.
21. Nakai S, Hirose T, Uwahodo Y, Imaoka T, Okazaki H, Miwa T, Nakai M, Yamada S, Dunn B, Burris KD, Molinoff PB, Tottori K, Altar CA & Kikuchi T, Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone, Eur J Pharmacol, 472 (2003) 89.
22. Ali O, Haleem D J, Obaid R, Kamil N, Haleem M A & Ahmed S W, Effect of co administration of haloperidol and large neutral amino acids (tryptophan and valine) on rats striatal dopamine, serotonin and their metabolism, Pak J Pharm Sci, 16 (2003) 13.
23. Brocco M, Dekeyne A, Veiga S, Girardon S & Millan M J, Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents, Pharmacol Biochem Behav, 71 (2002) 667.
24. Silva SR, Futuro-Neto HA & Pires J G, Inhibition of chlorpromazine-induced catalepsy by the 5-HT-1A ligands pindolol and buspirone in mice, Braz J Med Biol Res, 23 (1990) 869.
25. Pires J G, Fonseca F C, Woelffel A B & Futuro-Neto H A, Evidence of interaction between fluoxetine and isosorbide dinitrate on neuroleptic-induced catalepsy in mice, Braz J Med Biol Res, 31 (1998) 417.
26. Verhagen-Kamerbeek W D, Hazemeijer I, Korf J & Lakke J P, Attenuation of haloperidol-induced catalepsy by norepinephrine and L-threo-DOPS, J Neural Transm Park Dis Dement Sect, 6 (1993) 17.
27. Rogue P, Hanauer A, Zwiller J, Malviya A N & Vincendon G. Upregulation of dopamine D2 receptor mRNA in rat striatum by chronic haloperidol treatment, Eur J Pharmacol, 207 (1991) 165.
28. Barnes J M, Barnes N M & Couper S J, Behavioural pharmacology of 5HT3 receptor ligands, Neurosci Biobehav Rev, 16 (1992) 107.
29. Kapur S & Remington G, Serotonin- dopamine interaction and its relevance to schizophrenia. Am J Psychiatry, 153 (1996) 466.
30. Prehn J H, Welsch M, Backhauss C, Nuglisch J, Ausmeier F, Karkoutly C & Krieglstein J, Effects of serotonergic drugs on experimental brain ischemia: evidence for the protective role of serotonin in cerebral ischemia, Brain Res, 630: (1993) 10.
31. Semkova I, Wolz P & Krieglstein J, Neuroprotective effect of 5HT-1A receptor agonist, Bay X 3702, demonstrated in vitro and in vivo, Eur J Pharmacol, 359 (1998) 251.
32. Cahir M, Mawhinney T & King D J, Differential region specific regulation of central alpha1-adrenoceptor binding following chronic haloperidol and clozapine administration in rat, Psychopharmacology, 172 (2004)196.
33. Burger M B E, Fachineto R, Alves A, Callegari L & Rocha J B T, Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats, Brain Res, 1031 (2005) 202.